Risk factors and outcomes of metastatic poorly differentiated thyroid carcinoma

Table 3 Clinical features of five patients who developed metastatic disease during follow-up

Patient number	Age/Sex	TNM at diagnosis	Type of thyroid surgery	Time from PDTC diagnosis to metastasis (years)	Cumulative dose of RAI before metastasis (mCi)	Positive finding at detection	Sites of metastasis	Time from metastasis to death (years)	Cumulative dose of RAI (mCi)	External beam radiation therapy, dose (cGy)	Targeted therapy
1	44/F	T4N0M0	Total thyroidectomy	11.9	0	CT	Lung, bone	5.9	980	6000
2	51/F	T4N0M0	Total thyroidectomy	1.7	100	PET/CT	Lung	2.5	100	0	Lenvatinib, sorafenib, cabozantinib
3	58/F	T4N0M0	Total thyroidectomy	0.7	30	RAI scan	Lung	2.1	580	5000
4	62/F	T2N0M0	Total thyroidectomy	4.9	160	Chest X-ray	Lung, bone	3.2	835	4500
5	77/F	T3N0M0	Total thyroidectomy	0.9	30	Chest X-ray	Lung	0.6	60	0

CT: Computed tomography; PET: Positron emission tomography; RAI: Radioactive iodine; PDTC: Poorly differentiated thyroid carcinoma.